Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

Prospective Evaluation of Patient Preferences for Outcomes of Hormonal Agents and Chemotherapy in Combination With Androgen Deprivation Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05381311

Enrollment

1020

Registered

2022-05-19

Start date

2021-09-03

Completion date

2022-12-11

Last updated

2024-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Hormone-sensitive Prostate Cancer, Prostate Cancer

Keywords

prostate cancer, metastatic hormone-sensitive prostate cancer, observational

Brief summary

The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.

Detailed description

The study will develop and administer a discrete-choice experiment (DCE) to quantify tradeoff preferences of participants with mHSPC and locally-advanced prostate cancer in various countries. Data/surveys are being collected in: United States, Canada, UK, France, Spain, Japan, China and South Korea.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

For interviews (attribute prioritization and pretest interviews) * Diagnosis of mHSPC with or without previous experience with ADT * Able to read and understand the survey language * Able to provide informed consent For online survey * Diagnosis of mHSPC or locally-advanced prostate cancer with or without previous experience with ADT * Able to read and understand the survey language * Able to provide informed consent

Exclusion criteria

Not applicable

Design outcomes

Primary

Measure	Time frame	Description
Log-odds (preference weights) by participant cancer type and country	1 day (once through survey)	Log-odds indicate participants' relative preferences for treatments with each attribute level in the study, all else equal.

Secondary

Measure	Time frame	Description
Relative importance weights by participant type and country	1 day (once through survey)	These weights indicate the overall influence of each study attribute on choice.

Countries

United States

Outcome results